ArticleSmall (Weinheim an der Bergstrasse, Germany)2011
Preclinical evaluation of Raman nanoparticle biodistribution for their potential use in clinical endoscopy imaging.
Article in Small (Weinheim an der Bergstrasse, Germany), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- A Raman-based endoscopic strategy for multiplexed molecular imaging.Proceedings of the National Academy of Sciences of the United States of America · 2013Trial
- Feasibility of label-free multiphoton luminescence imaging to track the fate of inhaled gold nanoparticles inBiophotonics discovery · 2026Article
- Multimodal optical imaging strategy to evaluate the microscopic biodistribution of SERS gold nanoparticles across histology sections.Biophotonics discovery · 2026Article
- Simultaneous detection of lymphocytes and tumor cellsNanoscale horizons · 2026Article
- Multiphoton Luminescence Imaging: A Label-Free Tool for Visualizing the Long-Term Fate of Gold Nanoparticles in Tissue.ACS nano · 2025Article
- A Permeabilization Workflow To Enable Specific Multiplexed Profiling Using SERS Nanoparticles.ACS applied materials & interfaces · 2025Article
- In vivo surface-enhanced Raman scattering techniques: nanoprobes, instrumentation, and applications.Light, science & applications · 2025Review
- A Systematic Approach toward Enabling Maximal Targeting Efficiency of Cell Surface Proteins with Actively Targeted SERS Nanoparticles.ACS applied materials & interfaces · 2024Article
- Nanomaterial-based contrast agents.Nature reviews. Methods primers · 2023Article
- Radiolabeled nanomaterial for cancer diagnostics and therapeutics: principles and concepts.Cancer nanotechnology · 2023Review
- Emergence of Raman Spectroscopy as a Probing Tool for Theranostics.Nanotheranostics · 2023Review
- Application of nanotechnology in the early diagnosis and comprehensive treatment of gastrointestinal cancer.Journal of nanobiotechnology · 2022Review
- Advances in Surface Enhanced Raman Spectroscopy forNanotheranostics · 2022Review
- Article
- Multimodality Imaging Agents with PET as the Fundamental Pillar.Angewandte Chemie (International ed. in English) · 2019Review
- A Raman Imaging Approach Using CD47 Antibody-Labeled SERS Nanoparticles for Identifying Breast Cancer and Its Potential to Guide Surgical Resection.Nanomaterials (Basel, Switzerland) · 2018Article
- Emergence of two near-infrared windows for in vivo and intraoperative SERS.Current opinion in chemical biology · 2018Review
- Review
- Smart-Dust-Nanorice for Enhancement of Endogenous Raman Signal, Contrast in Photoacoustic Imaging, and T2-Shortening in Magnetic Resonance Imaging.Small (Weinheim an der Bergstrasse, Germany) · 2018Article
- In vivo biodistribution and toxicity of intravesical administration of quantum dots for optical molecular imaging of bladder cancer.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Raman imaging offers unsurpassed sensitivity and multiplexing capabilities. However, its limited depth of light penetration makes direct clinical translation challenging. Therefore, a more suitable way to harness its attributes in a clinical setting would be to couple Raman spectroscopy with endoscopy. The use of an accessory Raman endoscope in conjunction with topically administered tumor-targeting Raman nanoparticles during a routine colonoscopy could offer a new way to sensitively detect dysplastic lesions while circumventing Raman's limited depth of penetration and avoiding systemic toxicity. In this study, the natural biodistribution of gold surface-enhanced Raman scattering (SERS) nanoparticles is evaluated by radiolabeling them with (64) Cu and imaging their localization over time using micropositron emission tomography (PET). Mice are injected either intravenously (IV) or intrarectally (IR) with approximately 100 microcuries (μCi) (3.7 megabecquerel (MBq)) of (64) Cu-SERS nanoparticles and imaged with microPET at various time points post injection. Quantitative biodistribution data are obtained as % injected dose per gram (%ID g(-1)) from each organ, and the results correlate well with the corresponding microPET images, revealing that IV-injected mice have significantly higher uptake (p < 0.05) in the liver (5 h = 8.96% ID g(-1); 24 h = 8.27% ID g(-1)) than IR-injected mice (5 h = 0.09% ID g(-1); 24 h = 0.08% ID g(-1)). IR-injected mice show localized uptake in the large intestine (5 h = 10.37% ID g(-1); 24 h = 0.42% ID g(-1)) with minimal uptake in other organs. Raman imaging of excised tissues correlate well with biodistribution data. These results suggest that the topical application of SERS nanoparticles in the mouse colon appears to minimize their systemic distribution, thus avoiding potential toxicity and supporting the clinical translation of Raman spectroscopy as an endoscopic imaging tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.